LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

LLY

1,130.08

+0.44%↑

JNJ

232.65

+1.91%↑

ABBV

227.34

+1.09%↑

UNH

400.31

+0.89%↑

MRK

120.93

+0.57%↑

Strona główna・Stock List・United Therapeutics Corp

United Therapeutics Corp

Closed

SectorHealthcare

547.34 -0.04

Buy Sell

Overview

Share price change

24h

Current

Min

545

Max

550.33

Key metrics
By Trading Economics
Income	-89M 275M
Sales	-8.7M 782M
P/E Sector Avg	20.134 49.888
EPS	5.82
Profit margin	35.176
Employees	1,400
EBITDA	-176M 348M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+21.1% upside

Dividends
By Dow Jones
Next Earnings	29 lip 2026

Market Stats
By TradingEconomics
Market Cap	-1.5B 23B
Previous open	547.38
Previous close	547.34

News Sentiment

By Acuity

50%

134 / 344 Ranking in Healthcare

United Therapeutics Corp Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

5 cze 2026, 19:20 UTC

Major Market Movers

Meta Platforms Slips on Report of Plans for Multibillion-Dollar Offering to Fund AI Buildout

6 cze 2026, 08:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

6 cze 2026, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

6 cze 2026, 04:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 cze 2026, 00:14 UTC

Acquisitions, Mergers, Takeovers

4 Arm Execs Sold $26 Million in Stock, but They Missed a High -- Barrons.com

5 cze 2026, 21:27 UTC

Earnings

Carnage in Chip Stocks Hits Extra Hard in Top-Heavy Market -- WSJ

5 cze 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 cze 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

5 cze 2026, 20:20 UTC

Acquisitions, Mergers, Takeovers

Altice France Group Had Granted Initial Exclusivity Period to Consortium Until May 15, Which Was Then Extended to June 5

5 cze 2026, 20:19 UTC

Acquisitions, Mergers, Takeovers

Altice France Group, Bouygues Telecom, Free-iliad Group, Orange Exclusivity Period Extended by 48 Hours

5 cze 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 cze 2026, 19:26 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 cze 2026, 19:26 UTC

Market Talk

Hog Futures Tumble to Close Week -- Market Talk

5 cze 2026, 19:10 UTC

Market Talk

Canada's GDP Targets From AI-Related Spending Require Second Look -- Market Talk

5 cze 2026, 19:03 UTC

Market Talk

Oil Falls As Market Holds Out Hope for End to Conflict -- Market Talk

5 cze 2026, 18:59 UTC

Market Talk

U.S. Natural-Gas Futures Pull Back After Gains -- Market Talk

5 cze 2026, 18:47 UTC

Market Talk

Canada's Labor Market 'Retains Some Weakness' Despite Stellar May Report -- Market Talk

5 cze 2026, 18:34 UTC

Market Talk

Hyperliquid ETFs Have Inflows Despite Crypto Weakness -- Market Talk

5 cze 2026, 18:33 UTC

Acquisitions, Mergers, Takeovers

The U.S. Government Could Take a Stake in OpenAI. What That Means for Tech Stocks. -- Barrons.com

5 cze 2026, 17:50 UTC

Earnings

Lululemon Slumps on Earnings. Bargain Hunters Beware. -- Barrons.com

5 cze 2026, 17:27 UTC

Market Talk

U.S. Oil Rig Count Rises for 6th Straight Week -- Market Talk

5 cze 2026, 16:48 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 cze 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5 cze 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

5 cze 2026, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

5 cze 2026, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

5 cze 2026, 15:44 UTC

Acquisitions, Mergers, Takeovers

Ryan Cohen Is Ready to Talk About eBay. For Real. -- Barrons.com

5 cze 2026, 15:26 UTC

Market Talk

Gold Down Nearly 3% On Rate Hike Concerns After U.S. Hiring Data -- Market Talk

5 cze 2026, 15:25 UTC

Earnings

Quantinuum Trades Below Offer Price. Why the Quantum Stock Is Sliding. -- Barrons.com

5 cze 2026, 15:16 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Peer Comparison

Price change

United Therapeutics Corp Forecast

Price Target

By TipRanks

21.1% upside

12 Months Forecast

Average 665.9 USD 21.1%

High 738 USD

Low 516 USD

Based on 10 Wall Street analysts offering 12 month price targets forUnited Therapeutics Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Based on 10 analysts giving stock ratings to United Therapeutics Corp - Dist in the past 3 months.

Sentiment

By Acuity

134 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About United Therapeutics Corp

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.